Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftazidime/Avibactam PK in Peritoneal Dialysis and Critically Ill Pneumonia Patients
NCT03790176Phase 1Unknown
- Start
- Oct 2018
- Primary completion
- Dec 2022
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label trial of ceftazidime + avibactam in peritonitis, hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) (2 cohorts). Primary endpoint: Area under the concentration time curve from 0 to 8 hours. Status: unknown.
02
Drugs
ceftazidime + avibactam
03
Conditions
peritonitishospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on NCT03790176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03790176.